(Q53842727)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

3-[2-butyl-1-[2-(diethylamino)ethyl]-5-benzimidazolyl]-N-hydroxy-2-propenamide

8 March 2020

main subject

phase II clinical trial

0 references

1 reference

ChEBI release 2020-05-28

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bernhard Eigl

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

S North

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Winquist

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D Finch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

L Wood

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

S S Sridhar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J Powers

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J Good

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M Sharma

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J Bazov

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

T Jamaspishvili

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M E Cox

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

P A Bradbury

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E A Eisenhauer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

K N Chi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

19 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

969-976

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25983041%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4

8 March 2020

exact match

0 references

cites work

The role of histone deacetylases in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Role of molecular chaperones in steroid receptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

TMPRSS2-ERG and PTEN loss in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Analyzing real-time PCR data by the comparative C(T) method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Histone deacetylase interacts directly with DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0252-4

HDAC inhibitors and cardiac safety

21 January 2018

1 reference

12 December 2020

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells

1 reference

12 December 2020

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study

1 reference

12 December 2020

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

1 reference

12 December 2020

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

1 reference

12 December 2020